Bill Ackman, head of Pershing Square Capital Management, said his firm's presentation of a Herbalife investigation will "expose incredible fraud."» Read More
WASHINGTON, July 24- A U.S. lawmaker will pressure the U.S. Securities and Exchange Commission on Thursday to consider a raft of reforms, after William Ackman's aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting.
Microsoft makes design central to its future. Before Ralf Groene helped devise the look and feel of Microsoft's Surface tablet, he designed food— or "food concepts," he says, such as dried noodles that come wrapped around a pair of chopsticks and a fork that squeezes out sauce.
July 21- Investor William Ackman, who owns nearly 10 percent of Botox maker Allergan Inc, said on Monday that the likelihood of Valeant Pharmaceuticals International Inc succeeding in its hostile takeover for Allergan increased on Monday.
NEW YORK, July 21- U.S. stocks fell on Monday, following the sharpest moves in indexes in the past three months during the two previous sessions, as developments in Ukraine and Gaza continue to garner investor focus.
July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, said on Monday that it would cut 13 percent of its global workforce as part of a restructuring meant to boost profits over the next six years.
July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, on Monday announced 1,500 jobs cuts as part of a $475 million restructuring meant to boost profits over the next six years.
Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals. Allergan Inc. has rejected several takeover attempts from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman's Pershing Square Capital Management.
July 21- Allergan Inc, which is fighting off a hostile bid from Valeant Pharmaceuticals International Inc, on Monday said that its second-quarter profit and sales rose, and it announced $475 million in cost cuts.
July 17- Allergan Inc, trying to fend off a hostile takeover bid from Valeant Pharmaceuticals International Inc, has thrown up obstacles to a special shareholders meeting, its biggest investor said on Thursday.
July 17- Allergan Inc, trying to fend off a hostile takeover bid from Valeant Pharmaceuticals International Inc, has stacked the odds against a special shareholders meeting, its biggest investor said on Thursday.
The billionaire investors, who have been at odds over nutrition and diet company Herbalife, made up in public on Wednesday, ending a decade long feud that exploded on cable television 18 months ago.
NEW YORK, July 16- Billionaire investor John Paulson on Wednesday called Valeant Pharmaceuticals International Inc a "very serious acquirer" and predicted that Allergan Inc cannot rebuff the drug maker on its own.
John Paulson, founder of hedge fund firm Paulson & Co., said corporate M&A activity "will continue for the foreseeable future."
Novartis and Google have agreed to develop "smart" contact lenses to help diabetics track blood glucose levels or restore the eye's ability to focus.
July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.
Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.
July 11- Allergan Inc advised its stockholders to refrain from taking any action in response to Pershing Square Capital Management's proposal to replace a majority of the botox maker's board.
While you might not know their names now, you will. They are five hedge fund stars of the future as identified by Institutional Investor.
In his quest to fend off a hostile takeover attempt, has Allergan CEO David Pyott got something powerful up his sleeve?
July 8- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the toenail. The topical solution, Kerydin, is expected to be launched as early as the end of the quarter in the United States, the company said on Tuesday.